Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Clinical studies: Broad definition of commercially confidential information endangers transparency

2015-02-23 EMA’s commenting period for the transparency aspect of the EU study database specifications ended on the 18th of February. IQWiG has now published its comment.  read more Link to "Clinical studies: Broad definition of commercially confidential information endangers transparency"

Daclatasvir for hepatitis C: hint of added benefit in genotype 4

2015-02-19 A hint of an added benefit can be derived from the drug manufacturer’s data subsequently submitted. However, the extent cannot be exactly estimated.  read more Link to "Daclatasvir for hepatitis C: hint of added benefit in genotype 4"

Simoctocog alfa for haemophilia A: no suitable data

2015-02-16 No added benefit can be derived from the dossier: The duration of the direct comparative studies was too short and the study pool on one-arm studies with the comparator therapy was incomplete.  read more Link to "Simoctocog alfa for haemophilia A: no suitable data"

Lurasidone in schizophrenia: added benefit is not proven

2015-02-02 Lurasidone shows no added benefit for acute treatment or as prevention of relapse. It is uncertain whether its effect on schizophrenia symptoms is as good as that of comparator therapies.  read more Link to "Lurasidone in schizophrenia: added benefit is not proven"

Sipuleucel-T in prostate cancer: added benefit is not proven

2015-01-02 Data on survival were not evaluable because group differences might have been caused by the circumstances of the subsequent therapies. Certain side effects such as fever are more frequent.  read more Link to "Sipuleucel-T in prostate cancer: added benefit is not proven"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
N14-02 Systemic therapy in adults as a psychotherapeutic approach on the report plan 2015-03-26

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Propranolol (Hemangiol) for infants with hemangioma

Propranolol (trade name Hemangiol) has been approved for the treatment of infants aged 5 weeks and older with a growing hemangioma since April 2014. A hemangioma is a nodule formed by blood vessels.  read more (Link to "Propranolol (Hemangiol) for infants with hemangioma" – opens in a new window)

to top

Glossary entries